Tryp Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRYPF research report →
About the company
Tryp Therapeutics Inc. is a biopharmaceutical company dedicated to identifying and advancing novel therapeutic compounds for medical conditions characterized by significant unmet needs. Its flagship development initiative, known as PFN, focuses on addressing neuropsychiatric disorders by utilizing precisely formulated synthetic psilocybin.
- CEO
- Jason Carroll
- IPO
- 2021
- HQ
- Kelowna, BC, CA
Price Chart
- Market Cap
- $5.42M
- P/E
- -1.10
- P/S
- 0.00
- P/B
- -1.54
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 402.50%
- ROIC
- 356.62%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,267,073 · 29.73%
- EPS
- $-0.05 · 43.13%
- Op Income
- $-4,701,745
- FCF YoY
- 38.96%
- 52W High
- $0.09
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.04
- Beta
- -1.28
- Avg Volume
- 49.24K
Get TickerSpark's AI analysis on TRYPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TRYPF coverage
Recent articles, reports, and earnings notes.
No research on TRYPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRYPF report →Similar companies
Peers in the same neighborhood.